299660.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 13:35):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
今日成交量	65 098
平均成交量	112 591
市值	42.52B
EPS	KRW-241.94 ( Q1 \| 2024-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW3.72 (0.18%)

相关性 (AI algo v.1.1b): Undervalued: 0.03% KRW2 015.54 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: -0.05 (neutral)

短: 0.40 (neutral)

Signal:(56.176) Neutral

Cellid, Co., Ltd. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cellid, Co., Ltd. 相关性 - 货币/商品

-0.05
( neutral )

-0.45
( neutral )

0.42
( neutral )

-0.11
( neutral )

0.50
( neutral )

0.43
( neutral )

Cellid, Co., Ltd. 财务报表

Annual	2023
营收:	KRW0
毛利润:	KRW-2.66B (0.00 %)
EPS:	KRW-1 078.05

FY	2023
营收:	KRW0
毛利润:	KRW-2.66B (0.00 %)
EPS:	KRW-1 078.05

FY	2022
营收:	KRW480.00M
毛利润:	KRW-2.38B (-495.54 %)
EPS:	KRW-2 141.24

Financial Reports:

No articles found.

Cellid, Co., Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cellid, Co., Ltd.

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.